| Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL (NCT07569965) | Miltenyi Biomedicine GmbH | 2026-09-01 |
| PRAISE-IR Versus CIBMTR Controls (NCT07717164) | Miltenyi Biomedicine GmbH | 2026-07-31 |
| US Zamto-cel Autoimmune Diseases (NCT06708845) | Miltenyi Biomedicine GmbH | 2026-07-01 |
| MB-CART2019.1 in Refractory Multiple Sclerosis (NCT07178431) | Miltenyi Biomedicine GmbH | 2026-04-01 |
| M-2018-334 in Hematological Malignancies (NCT06225050) | Miltenyi Biomedicine GmbH | 2026-02-28 |
| DALY II Japan/MB-CART2019.1 for DLBCL (NCT07288879) | Miltenyi Biomedicine GmbH | 2025-12-11 |
| Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms (NCT06508931) | Miltenyi Biomedicine GmbH | 2025-08-04 |
| MB-CART19.1 in Refractory SLE (NCT06189157) | Miltenyi Biomedicine GmbH | 2024-08-12 |
| MB-dNPM1-TCR.1 in Relapsed/Refractory AML (NCT06424340) | Miltenyi Biomedicine GmbH | 2024-08-01 |
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU (NCT06116110) | Miltenyi Biomedicine GmbH | 2024-05-15 |
| CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease (NCT06347718) | Miltenyi Biomedicine GmbH | 2023-07-17 |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (NCT04844866) | Miltenyi Biomedicine GmbH | 2021-08-18 |
| DALY II USA/ MB-CART2019.1 for DLBCL (NCT04792489) | Miltenyi Biomedicine GmbH | 2021-05-25 |
| A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers (NCT04405466) | Miltenyi Biomedicine GmbH | 2020-04-22 |
| MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) (NCT03853616) | Miltenyi Biomedicine GmbH | 2018-11-26 |
| MB-CART20.1 Lymphoma (NCT03664635) | Miltenyi Biomedicine GmbH | 2018-09-25 |